About
Our Story
Driven To Do More
Every day, we come to work focused and driven by the opportunity to deliver the next best-in-class therapy for patients with genetically defined diseases – to move beyond incremental improvements and solely treating symptoms, to address the real causes of disease. We are methodical, rational, and intentional in our approach to identify pragmatic solutions to complex health challenges with the goal of restoring health and allowing patients to live better, longer lives.
Our Mission
To design rational precision therapies that treat the underlying cause of disease to improve patients’ lives.
Our Vision
To discover, develop, and commercialize best-in-class therapies that have a dramatic impact for patients with genetically defined diseases.
Leadership
The Cogent team is driven to discover and develop novel precision medicines. Beginning with bezuclastinib, we strive to improve the lives of patients fighting rare, genetically driven diseases.
Andrew RobbinsCEO and President
Board of Directors
Research Leadership

John Robinson, PhD
Chief Scientific Officer

Brad Fell
VP, Head of
Medicinal Chemistry

Francis Sullivan, PhD
VP, Enzymology and
Structural Biology

Shannon Winski, PhD
VP, Pharmacology and
Toxicology
Scientific Advisory Board